Abstract
HBV carrier rate is now 0.67% in Japanese population. The most prevalent HBV genotype is genotype C (85%) in patients with chronic HBV carriers in Japan. Hepatitis activity is more severe and response to anti-viral therapy is poor in genotype C compared with genotype B. There are questions whether we should use lamivudine for long-term.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudineuntreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584–586.
Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145–1153.
Ide T, Kumashiro R, Suzuki H, Tanikawa K, Sata M. Two-year follow-up study after treatment with lamivudine for chronic hepatitis B: seven cases reported. Hepatol Res 2000;17:197–204.
Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Thl response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000;32:604–609.
Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001;34:573–577.
Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, Panella C, Francavilla A. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001;35:805–810.
Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 2001;34:583–589.
Ide T, Kumashiro R, Sata M, et al. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. Am J Gastroenterol 2003;98:2048–51.
Ide T, Kumashiro R, Hino T, Murashima S, Ogata K, Koga Y, Sata M. Transcription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine. Hepatol Res 2001;21:76–84.
Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, Peltekian K, Wong F, Margulies M, Heathcote EJ. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207–210.
Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000;33:308–312.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Japan
About this paper
Cite this paper
Sata, M. (2004). Lamivudine Therapy of Hepatitis B in Japan. In: Omata, M., Okita, K. (eds) Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-53977-3_3
Download citation
DOI: https://doi.org/10.1007/978-4-431-53977-3_3
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-67975-2
Online ISBN: 978-4-431-53977-3
eBook Packages: Springer Book Archive